[{"address1": "2155 Park Boulevard", "city": "Palo Alto", "state": "CA", "zip": "94306", "country": "United States", "phone": "650 272 6138", "fax": "650 618 1621", "website": "https://www.eigerbio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia. The company is headquartered in Palo Alto, California. On April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.", "fullTimeEmployees": 25, "companyOfficers": [{"maxAge": 1, "name": "Dr. David  Apelian M.B.A., M.D., Ph.D.", "age": 58, "title": "CEO & Director", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 847026, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James  Vollins J.D.", "age": 54, "title": "General Counsel, Chief Compliance Officer & Corporate Secretary", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 453756, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher A. Kurtz", "age": 56, "title": "Chief Technical Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Douglas  Staut", "title": "Chief Restructuring Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1722470400, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 12.625, "open": 12.5, "dayLow": 12.025, "dayHigh": 12.5, "regularMarketPreviousClose": 12.625, "regularMarketOpen": 12.5, "regularMarketDayLow": 12.025, "regularMarketDayHigh": 12.5, "beta": 2.791, "forwardPE": -3.402778, "volume": 664, "regularMarketVolume": 664, "averageVolume": 17829, "averageVolume10days": 10700, "averageDailyVolume10Day": 10700, "bid": 13.03, "ask": 17.25, "bidSize": 46000, "askSize": 40000, "marketCap": 18139800, "fiftyTwoWeekLow": 1.1, "fiftyTwoWeekHigh": 28.5, "priceToSalesTrailing12Months": 1.1500539, "fiftyDayAverage": 9.7368, "twoHundredDayAverage": 6.90602, "currency": "USD", "enterpriseValue": -16178078, "floatShares": 1325920, "sharesOutstanding": 1480800, "sharesShort": 29810, "sharesShortPriorMonth": 41440, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.0201, "heldPercentInsiders": 0.070310004, "heldPercentInstitutions": 0.24047, "shortRatio": 1.6, "shortPercentOfFloat": 0.028499998, "bookValue": -9.772, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -74963000, "trailingEps": -11.74, "forwardEps": -3.6, "enterpriseToRevenue": -1.026, "enterpriseToEbitda": 0.226, "exchange": "OEM", "quoteType": "EQUITY", "symbol": "EIGRQ", "underlyingSymbol": "EIGRQ", "shortName": "Eiger BioPharmaceuticals, Inc.", "longName": "Eiger BioPharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1391092200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "db3d2481-ac37-3b26-bcbc-7a221a994156", "gmtOffSetMilliseconds": -14400000, "currentPrice": 12.25, "targetHighPrice": 30.0, "targetLowPrice": 30.0, "targetMeanPrice": 30.0, "targetMedianPrice": 30.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 1, "totalCash": 31726448, "totalCashPerShare": 21.425, "ebitda": -71511000, "quickRatio": 0.517, "currentRatio": 0.71, "totalRevenue": 15773000, "revenuePerShare": 10.685, "returnOnAssets": -0.56448, "returnOnEquity": -3.6699798, "freeCashflow": -53257500, "operatingCashflow": -74548000, "revenueGrowth": -0.869, "grossMargins": 0.99848, "operatingMargins": -6.38889, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-12"}]